Inicio
Detalle del título uniforme
Chemotherapy Research and Practice
Tipo de obra :
Autre
Naturaleza de la obra :
Oeuvre
|
Documentos disponibles con este título uniforme (1)
Clasificado(s) por (Año de edición descendente) Refinar búsqueda
Methodology for anti-gene anti-IGF-I therapy of malignant tumours / Beatriz Helena Aristizábal Bernal
Título : Methodology for anti-gene anti-IGF-I therapy of malignant tumours Tipo de documento : documento electrónico Autores : Beatriz Helena Aristizábal Bernal, Fecha de publicación : 2012 Títulos uniformes : Chemotherapy Research and Practice Idioma : Inglés (eng) Resumen : The aim of this study was to establish the criteria for methodology of cellular “anti-IGF-I” therapy of malignant tumours and particularly for glioblastoma multiforme. The treatment of primary glioblastoma patients using surgery, radiotherapy, and chemotherapy was followed by subcutaneous injection of autologous cancer cells transfected by IGF-I antisense/triple helix expression vectors. The prepared cell “vaccines” should it be in the case of glioblastomas or other tumours, have shown a change of phenotype, the absence of IGF-I protein, and expression of MHC-I and B7. The peripheral blood lymphocytes, PBL cells, removed after each of two successive vaccinations, have demonstrated for all the types of tumour tested an increasing level of CD8+ and CD8+28+ molecules and a switch from CD8+11b+ to CD8+11. All cancer patients were supervised for up to 19 months, the period corresponding to minimum survival of glioblastoma patients. The obtained results have permitted to specify the common criteria for “anti-IGF-I” strategy: characteristics sine qua non of injected “vaccines” (cloned cells IGF-I(−) and MHC-I(+)) and of PBL cells (CD8+ increased level). Mención de responsabilidad : Jerzy Trojan, Yuexin X. Pan, Ming X. Wei, Adama Ly, Alexander Shevelev, Maciej Bierwagen, Marie-Yvonne Ardourel, Ladislas A. Trojan, Alvaro Alvarez, Christian Andres, Maria C. Noguera, Ignacio Briceno, Beatriz H. Aristizabal, Heliodor Kasprzak, Huynh T. Duc, and Donald D. Anthony Referencia : Chemother Res Pract. 2012;2012:721873. DOI (Digital Object Identifier) : 10.1155/2012/721873 PMID : 22400112 Derechos de uso : CC BY En línea : https://www.hindawi.com/journals/cherp/2012/721873/ Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4917 Methodology for anti-gene anti-IGF-I therapy of malignant tumours [documento electrónico] / Beatriz Helena Aristizábal Bernal, . - 2012.
Obra : Chemotherapy Research and Practice
Idioma : Inglés (eng)
Resumen : The aim of this study was to establish the criteria for methodology of cellular “anti-IGF-I” therapy of malignant tumours and particularly for glioblastoma multiforme. The treatment of primary glioblastoma patients using surgery, radiotherapy, and chemotherapy was followed by subcutaneous injection of autologous cancer cells transfected by IGF-I antisense/triple helix expression vectors. The prepared cell “vaccines” should it be in the case of glioblastomas or other tumours, have shown a change of phenotype, the absence of IGF-I protein, and expression of MHC-I and B7. The peripheral blood lymphocytes, PBL cells, removed after each of two successive vaccinations, have demonstrated for all the types of tumour tested an increasing level of CD8+ and CD8+28+ molecules and a switch from CD8+11b+ to CD8+11. All cancer patients were supervised for up to 19 months, the period corresponding to minimum survival of glioblastoma patients. The obtained results have permitted to specify the common criteria for “anti-IGF-I” strategy: characteristics sine qua non of injected “vaccines” (cloned cells IGF-I(−) and MHC-I(+)) and of PBL cells (CD8+ increased level). Mención de responsabilidad : Jerzy Trojan, Yuexin X. Pan, Ming X. Wei, Adama Ly, Alexander Shevelev, Maciej Bierwagen, Marie-Yvonne Ardourel, Ladislas A. Trojan, Alvaro Alvarez, Christian Andres, Maria C. Noguera, Ignacio Briceno, Beatriz H. Aristizabal, Heliodor Kasprzak, Huynh T. Duc, and Donald D. Anthony Referencia : Chemother Res Pract. 2012;2012:721873. DOI (Digital Object Identifier) : 10.1155/2012/721873 PMID : 22400112 Derechos de uso : CC BY En línea : https://www.hindawi.com/journals/cherp/2012/721873/ Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4917 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001501 AC-2012-128 Archivo digital Producción Científica Artículos científicos Disponible